Innate Pharma Files Its 2020 Universal Registration Document (Document D’enregistrement Universel) and 2020 Annual Report on Form 20-F
28 avr. 2021 01h00 HE
|
INNATE PHARMA
MARSEILLE, France, April 28, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2020...
Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 28, 2021
21 avr. 2021 01h00 HE
|
INNATE PHARMA
The Annual General Meeting will be broadcasted live by the Company Shareholders are invited to vote at the General Meeting either by mail or by proxy MARSEILLE, France, April 21, 2021 (GLOBE...
Innate Pharma Annonce la Tenue de son Assemblée Générale 28 Mai 2021
21 avr. 2021 01h00 HE
|
INNATE PHARMA
L’Assemblée Générale sera retransmise en direct par la Société Les actionnaires sont invités à voter à l’Assemblée Générale par correspondance ou par procuration Marseille, France, 21 avr. 2021 ...
Innate Pharma to Hold its Annual General Meeting of Shareholders on May 28, 2021
21 avr. 2021 01h00 HE
|
INNATE PHARMA
The Annual General Meeting will be broadcasted live by the Company Shareholders are invited to vote at the General Meeting either by mail or by proxy Marseille, France, April 21, 2021 (GLOBE...
NOUVEAU NOMBRE D’ACTIONS ET DE DROITS DE VOTE D’INNATE PHARMA AU 1ER AVRIL 2021
19 avr. 2021 01h00 HE
|
INNATE PHARMA
Marseille, France, 19 avr. 2021 (GLOBE NEWSWIRE) -- Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate...
NUMBER OF SHARES AND VOTING RIGHTS OF INNATE PHARMA AS OF APRIL 1, 2021
19 avr. 2021 01h00 HE
|
INNATE PHARMA
Marseille, France, April 19, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des...
Number of Shares and Voting Rights of Innate Pharma as of April 1, 2021
19 avr. 2021 01h00 HE
|
INNATE PHARMA
MARSEILLE, France, April 19, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des...
Innate Pharma présente ses résultats financiers et l'avancée de son portefeuille pour l'année 2020
18 mars 2021 02h00 HE
|
INNATE PHARMA
Marseille, 18 mars 2021 (GLOBE NEWSWIRE) -- Lacutamab a reçu le statut « PRIME » de l’Agence Européenne du Médicament dans le syndrome de Sézary ; le programme de développement clinique avance dans...
Innate Pharma reports Full Year 2020 financial results and business update
18 mars 2021 02h00 HE
|
INNATE PHARMA
Marseille, March 18, 2021 (GLOBE NEWSWIRE) -- Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides...
Innate Pharma Reports Full Year 2020 Financial(1) Results and Business Update
18 mars 2021 02h00 HE
|
INNATE PHARMA
Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and peripheral T-cell lymphomaCompany’s first NK...